Format

Send to

Choose Destination
Methods Mol Biol. 2017;1521:183-193.

Gene Transfer in Cardiomyocytes Derived from ES and iPS Cells.

Author information

1
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA. francesca.stillitano@mssm.edu.
2
Division of Cardiovascular Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.
3
Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA, 94305, USA.
4
Cardiovascular Research Center, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Place, Box 1030, New York, NY, 10029, USA.

Abstract

The advent of human induced pluripotent stem cell (hiPSC) technology has produced patient-specific hiPSC derived cardiomyocytes (hiPSC-CMs) that can be used as a platform to study cardiac diseases and to explore new therapies.The ability to genetically manipulate hiPSC-CMs not only is essential for identifying the structural and/or functional role of a protein but can also provide valuable information regarding therapeutic applications. In this chapter, we describe protocols for culture, maintenance, and cardiac differentiation of hiPSCs. Then, we provide a basic procedure to transduce hiPSC-CMs.

KEYWORDS:

Cardiac differentiation; Gene therapy; Human pluripotent stem cells (hPSCs); Transduction; hPSC-derived cardiomyocytes

PMID:
27910049
DOI:
10.1007/978-1-4939-6588-5_12
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center